Editing Titanium (section)

=== Anticancer therapy studies ===
Following the success of [[cisplatin|platinum-based]] chemotherapy, titanium(IV) complexes were among the first non-platinum compounds to be tested for cancer treatment. The advantage of titanium compounds lies in their high efficacy and low toxicity ''[[in vivo]]''.<ref name=Tshuva-Miller/> In biological environments, hydrolysis leads to the safe and inert titanium dioxide. Despite these advantages the first candidate compounds failed clinical trials due to insufficient efficacy to toxicity ratios and formulation complications.<ref name=Tshuva-Miller/> Further development resulted in the creation of potentially effective, selective, and stable titanium-based drugs.<ref name=Tshuva-Miller>{{cite book |last1=Tshuva |first1=Edit Y. |last2=Miller |first2=Maya |editor1-last=Sigel |editor1-first=Astrid |editor2-last=Sigel |editor2-first=Helmut|editor3-last=Freisinger |editor3-first=Eva |editor4-last=Sigel |editor4-first=Roland K.O. |year=2018 |title=Metallo-drugs: Development and action of anticancer agents |series=Metal Ions in Life Sciences |volume=18 |doi=10.1515/9783110470734-014 |pmid=29394027 |publisher=de Gruyter GmbH |location=Berlin, DE |chapter=Chapter&nbsp;8. Coordination complexes of titanium(IV) for anticancer therapy |pages=219–250 |isbn=978-3-11-047073-4 |chapter-url=https://books.google.com/books?id=4nBLDwAAQBAJ}}</ref>